{"id":2212,"date":"2026-08-07T15:10:00","date_gmt":"2026-08-07T15:10:00","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=2212"},"modified":"2026-08-07T15:10:00","modified_gmt":"2026-08-07T15:10:00","slug":"everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/","title":{"rendered":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson)"},"content":{"rendered":"

Tuberous sclerosis complex is a rare inherited condition that causes a combination of widespread tumours, epilepsy and neuropsychological problems including autism and learning difficulties. Everolimus is an effective drug for treating the tumours and epilepsy. This paper reports a clinical trial of twenty-four weeks of everolimus treatment compared with placebo (an identical appearing pill without everolimus in it) for neuropsychological problems in adults with tuberous sclerosis complex. Surprisingly, these problems improved in both those receiving everolimus and those receiving placebo. This could reflect participants becoming familiar with the tests and staff \u2013 a finding that may help design of future trials. (https:\/\/jmg.bmj.com\/content\/early\/2026\/08\/06\/jmg-2026-111529<\/a>)<\/p>\n","protected":false},"excerpt":{"rendered":"

Tuberous sclerosis complex is a rare inherited condition that causes a combination of widespread tumours, epilepsy and neuropsychological problems including autism and learning difficulties. Everolimus is an effective drug for treating the tumours and epilepsy. This paper reports a clinical trial of twenty-four weeks of everolimus treatment compared with placebo (an identical appearing pill without […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2212","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nEverolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Tuberous sclerosis complex is a rare inherited condition that causes a combination of widespread tumours, epilepsy and neuropsychological problems including autism and learning difficulties. Everolimus is an effective drug for treating the tumours and epilepsy. This paper reports a clinical trial of twenty-four weeks of everolimus treatment compared with placebo (an identical appearing pill without [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-07T15:10:00+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson)\",\"datePublished\":\"2026-08-07T15:10:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/\"},\"wordCount\":133,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/\",\"name\":\"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2026-08-07T15:10:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2026\\\/08\\\/07\\\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/","og_locale":"en_US","og_type":"article","og_title":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog","og_description":"Tuberous sclerosis complex is a rare inherited condition that causes a combination of widespread tumours, epilepsy and neuropsychological problems including autism and learning difficulties. Everolimus is an effective drug for treating the tumours and epilepsy. This paper reports a clinical trial of twenty-four weeks of everolimus treatment compared with placebo (an identical appearing pill without [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/","og_site_name":"JMG Contact blog","article_published_time":"2026-08-07T15:10:00+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson)","datePublished":"2026-08-07T15:10:00+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/"},"wordCount":133,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/","url":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/","name":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2026-08-07T15:10:00+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2026\/08\/07\/everolimus-for-the-treatment-of-neuropsychological-deficits-in-tuberous-sclerosis-complex-findings-from-the-tron-multicentre-randomised-controlled-trial-contributed-by-dr-julian-r-sampson\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Everolimus for the treatment of neuropsychological deficits in tuberous sclerosis complex: findings from the TRON multicentre randomised controlled trial (Contributed by Dr Julian R Sampson)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/2212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=2212"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/2212\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=2212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=2212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=2212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}